SC 13G/A: Immatics N.V.

AI Summary

SC 13G/A filing by Immatics N.V..

Risk Assessment

Risk Level: low

Filing Documents

• tm242424d18_sc13ga.htm (SC 13G/A) — 82KB
• 0001104659-24-023732.txt ( ) — 84KB

(a)

Item 1(a) Name of Issuer: Immatics N.V. (the “Issuer”)

(b)

Item 1(b) Address of Issuer’s Principal Executive Offices: Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany

(a)

Item 2(a) Name of Person Filing: This Amendment No. 2 is being filed jointly by the Reporting Persons.

(b)

Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690

(c)

Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

(d)

Item 2(d) Title of Class of Securities: Ordinary Shares, nominal value £0.01 per share (“Ordinary Shares”).

(e)

Item 2(e) CUSIP Number: N44445109 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act. (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein by reference. Set forth below is the aggregate number of Ordinary Shares directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons. The information set forth below is based on 84,656,114 Ordinary Shares outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the Securities and Exchange Commission on January 17, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Name Number of Ordinary Shares we own or have the right to acquire within 60 days Percent of Clas

View Full Filing

View this SC 13G/A filing on SEC EDGAR